A platform to deliver silencing RNAs using exosomes

使用外泌体传递沉默 RNA 的平台

• 批准号: 539153-2019
• 负责人: Gibbings, Derrick
• 金额: $ 10.31万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=693555
• 关键词: platform; deliver; silencing; RNAs; using

In the past decade, scientists have discovered drugs that can specifically and potently inhibit the expression or function of proteins including antibodies and silencing RNAs. Silencing RNAs can profoundly inhibit expression of any gene, while antibodies can selectively bind specific versions of a protein, like those that misfiled and aggregate in neurodegeneration. A fundamental roadblock in the use of these two types of drugs for many diseases is there ability to accumulate in the tissues where they are required and cross the cell membrane to enter into cells where many of their targets are located. For example, silencing RNAs are life-changing new treatments for liver diseases, but cannot be used in other tissues because the current delivery vehicles are too inefficient and toxic. Recently, cells in our bodies were discovered to release tiny bubbles called exosomes that deliver contents from one cell into another. The Gibbings lab is developing methods to harness this natural ability of exosomes to deliver drugs like silencing RNAs to treat patients. Working with a pharmaceutical company the Gibbings lab will perform proof-of-principle experiments to test whether their discoveries about exosomes allow them to be used as a platform for delivery of silencing RNAs to treat patients. Successful completion of this project will train Canadians for employment in biotechnology and enable further development of these promising drug delivery vehicles by the pharmaceutical company with potential benefits to the Canadian economy and the health of Canadians. In addition, Dr. Gibbings aims to use these discoveries to launch a biotechnology company based in Canada which will provide further economic benefit to Canada.

在过去的十年中，科学家们已经发现了可以特异性和有效地抑制蛋白质（包括抗体和沉默RNA）表达或功能的药物。沉默RNA可以深刻地抑制任何基因的表达，而抗体可以选择性地结合蛋白质的特定版本，比如那些在神经变性中错误归档和聚集的蛋白质。在许多疾病中使用这两种类型的药物的基本障碍是能够在需要它们的组织中积累并穿过细胞膜进入它们的许多靶点所在的细胞。例如，沉默RNA是肝脏疾病的改变生命的新疗法，但不能用于其他组织，因为目前的递送载体效率太低且有毒。最近，我们体内的细胞被发现释放出称为外泌体的微小气泡，将内容物从一个细胞输送到另一个细胞。Gibbings实验室正在开发方法来利用外泌体的这种天然能力来提供药物，如沉默RNA来治疗患者。Gibbings实验室将与一家制药公司合作，进行原理验证实验，以测试他们关于外泌体的发现是否允许它们用作递送沉默RNA治疗患者的平台。该项目的成功完成将为加拿大人提供生物技术就业培训，并使制药公司能够进一步开发这些有前途的药物输送工具，对加拿大经济和加拿大人的健康有潜在的好处。此外，Gibbings博士的目标是利用这些发现在加拿大成立一家生物技术公司，为加拿大提供进一步的经济利益。